SCHEMBL23178209

SCHEMBL23178209

Cc1ccccc1Cn1c(=N)n(CC(O)c2ccc(Cl)c(Cl)c2)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 1/20 1.00
HTT P42858 5/20 0.64
POLB P06746 1/20 0.64
SLC2A1 P11166 1/20 0.61
NPSR1 Q6W5P4 4/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
MITF O75030 1/20 0.60
LMNA P02545 1/20 0.52
SLC5A2 P31639 4/20 0.52
PKM P14618 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CXCR3 P49682 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
HSD17B10 Q99714 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29822359 0.93 CBX7 (0.86) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL23144862 0.93 CBX7 (0.86) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL23144847 0.91 CBX7 (0.83) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL23144892 0.90 CBX7 (0.81) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL23177970 0.90 CBX7 (0.81) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL23145136 0.89 CBX7 (0.79) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL23682660 0.88 CBX7 (0.78) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL23144830 0.87 CBX7 (0.76) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL12084205 0.85 CBX7 (0.74) CBX7HTTPOLBSLC2A1NPSR1
SCHEMBL24760067 0.85 CBX7 (0.73) CBX7HTTPOLBSLC2A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-09-14 US disclosed
US-20230050819-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-02-16 US disclosed
US-20220402880-A1 BICYCLIC INHIBITORS OF CBX CHROMODOMAINS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-12-22 US disclosed
WO-2021061801-A1 BICYCLIC INHIBITORS OF CBX CHROMODOMAINS ICAHN SCHOOL OF MEDICINE AT MT. SINAI (US) 2021-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE NEDD4, CBL, UBQLN2 CBX7 1336/4885HTT 35/4885POLB 1167/4885
US-20230050819-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE CYFIP2, TPX2, ATXN2 CBX7 300/4885HTT 21/4885POLB 439/4885
US-20220402880-A1 BICYCLIC INHIBITORS OF CBX CHROMODOMAINS CBX2, CBX3, CBX7 CBX7 3/4885HTT 3837/4885POLB 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.